.jpeg)
Is Regorafenib a first-line targeted drug?
Regorafenib (Regorafenib) is a targeted therapy called a multikinase inhibitor. Kinases are proteins on or near the cell surface that carry important signals to the cell's control centers. Regorafenib blocks several kinase proteins that either help tumor cells grow or form new blood vessels to nourish tumors. Blocking these proteins can help stop the growth of cancer cells. Regorafenib, a drug used to treat advanced colorectal cancer, is often taken as a pill when other drugs are no longer effective. The dose of regorafenib was 150 or 160 mg/d during the first 3 weeks of each 4-week cycle.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
